Clinical Trial

Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of cariprazine in the treatment of schizophrenia in the adolescent population.
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2019-01-24; most recent amendment 2025-10-07.
Status change: Active, Not Recruiting → Recruiting 2022-02-18
Status change: Recruiting → Active, Not Recruiting 2020-10-28
Status change: Not Yet Recruiting → Recruiting 2019-06-10
Trial Details
NCT Number NCT03817502
Lead Sponsor Gedeon Richter Plc.
Conditions Schizophrenia
Enrollment 330 participants
Start Date 2019-06-06
Primary Completion 2026-12-15 (estimated)
Study Completion 2026-12-15 (estimated)
Updated on ClinicalTrials.gov 2025-10-08